A 28-year-old woman with a 10-year history of asthma presents to the clinic with complaints of nocturnal awakening 3–4 times per week, daytime symptoms on 4–5 days per week, and use of her salbutamol inhaler 5–6 times per week. She denies any recent respiratory tract infection. Physical examination reveals mild end-expiratory wheeze bilaterally. Spirometry shows FEV₁ of 72% predicted with a positive bronchodilator response. She is currently on salbutamol as needed only. What is the most appropriate next step in her asthma management?

Explanation

## Clinical Assessment This patient demonstrates **persistent asthma** based on symptom frequency and frequency of reliever use. The GINA 2023 classification identifies symptoms on ≥2 days per week (excluding nighttime only) as persistent asthma requiring controller therapy. **Key Point:** Nocturnal awakenings 3–4 times per week and daytime symptoms 4–5 days per week, plus reliever use 5–6 times per week, all indicate **uncontrolled intermittent asthma progressing toward persistent asthma**. ## Stepwise Asthma Management Algorithm ```mermaid flowchart TD A[Asthma Diagnosis Confirmed]:::outcome --> B{Symptom Frequency?}:::decision B -->|Symptoms ≤2 days/week<br/>Nighttime awakenings ≤2/month| C[Step 1: SABA as needed]:::action B -->|Symptoms >2 days/week OR<br/>Nighttime awakenings >2/month| D[Step 2: Low-dose ICS]:::action D --> E[Review in 2-4 weeks]:::action E --> F{Controlled?}:::decision F -->|Yes| G[Continue ICS maintenance]:::action F -->|No| H[Step 3: ICS + LABA]:::action C --> I{Symptoms worsen?}:::decision I -->|Yes| D ``` ## Why Low-Dose ICS? | Feature | Rationale | |---------|----------| | **Anti-inflammatory action** | Reduces airway hyperresponsiveness and prevents remodeling | | **Symptom control** | Reduces nocturnal awakenings and daytime symptoms within 2–4 weeks | | **Exacerbation prevention** | Reduces frequency and severity of acute exacerbations | | **Safety at low dose** | Minimal systemic absorption; local topical effect | | **GINA recommendation** | Step 2 therapy for all persistent asthma | **High-Yield:** ICS is the most effective anti-inflammatory agent for asthma and is the foundation of all persistent asthma treatment. Even low-dose ICS is superior to LABA monotherapy or increased SABA use. ## Why NOT the Other Options? - **SABA monotherapy (Option A):** Only appropriate for intermittent asthma with symptoms ≤2 days/week. This patient has persistent asthma and requires controller therapy. - **LABA monotherapy (Option C):** LABA must NEVER be used as monotherapy in asthma — it increases mortality if used without an ICS. LABA + ICS is Step 3 therapy, reserved for uncontrolled asthma on ICS alone. - **Immunotherapy (Option D):** Indicated only if allergic asthma is confirmed with specific IgE testing and allergen avoidance has failed. No mention of allergy or allergen exposure here. **Clinical Pearl:** The GINA 2023 update emphasizes that all patients with persistent asthma require ICS-containing therapy. SABA-only management is associated with poor outcomes and increased mortality risk.